Efficacy and safety of itolizumab, a novel anti-CD6 monoclonal antibody, in patients with moderate to severe chronic plaque psoriasis: results of a double-blind, randomized, placebo-controlled, phase-III study (Q35139830)
Jump to navigation
Jump to search
scientific article
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Efficacy and safety of itolizumab, a novel anti-CD6 monoclonal antibody, in patients with moderate to severe chronic plaque psoriasis: results of a double-blind, randomized, placebo-controlled, phase-III study |
scientific article |
Statements
1 reference
Efficacy and safety of itolizumab, a novel anti-CD6 monoclonal antibody, in patients with moderate to severe chronic plaque psoriasis: results of a double-blind, randomized, placebo-controlled, phase-III study (English)
1 reference
D S Krupashankar
Sunil Dogra
Leelavathy Budamakuntla
T K Sumathy
Radha Shah
M G Gopal
T Narayana Rao
C R Srinivas
Ramesh Bhat
Narendra Shetty
G Manmohan
Kotla Sai Krishna
Dalavoi Padmaja
Dasiga Venkata Subrahmanya Pratap
Vijay Garg
Sandesh Gupta
Neeraj Pandey
Uday Khopkar
Enrique Montero
M S Ramakrishnan
Pradip Nair
Prasanna C Ganapathi
2 April 2014
1 reference